Physician profile
Li Zhang
NPI 1972865863
$13,168.93
in general payments reported to CMS, 2019-2025
30 companies · $7,508 in 2025
The $7,508 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.61 · 2021: $28.04 · 2022: $791 · 2023: $2,087 · 2024: $2,698 · 2025: $7,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $1,544 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,468.75 |
| Food and Beverage | $1,544.25 |
| Education | $279.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,480.00 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,268.50 | 2024-2025 | Tagrisso, Enhertu, Calquence |
| Emd Serono, INC. | $1,800.93 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $1,711.25 | 2022-2023 | |
| Janssen Biotech, INC. | $1,469.91 | 2023-2025 | Erleada, Darzalex, Rybrevant |
| Aveo Pharmaceuticals, INC. | $1,000.00 | 2023 | Fotivda |
| Abbvie INC. | $275.75 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $166.22 | 2024-2025 | Onivyde |
| Daiichi Sankyo INC. | $145.09 | 2025 | Datroway, Enhertu |
| Glaxosmithkline, LLC. | $117.76 | 2025 | Jemperli, Ojjaara, Blenrep |
| Taiho Oncology, INC. | $111.55 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $91.09 | 2024 | Adstiladrin |
| Pfizer INC. | $68.55 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $59.55 | 2025 | Libtayo |
| Foundation Medicine, INC. | $56.61 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $54.19 | 2021-2025 | Opdualag |
| Merck Sharp & Dohme LLC | $40.65 | 2025 | Keytruda, Lynparza |
| Eisai INC. | $30.23 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $29.12 | 2025 | |
| Exelixis INC. | $28.14 | 2025 | Cabometyx |
| Tempus Ai, INC | $24.45 | 2025 | Xt Cdx |
| Sumitomo Pharma America, INC. | $24.33 | 2025 | Orgovyx |
| Sobi, INC | $21.38 | 2025 | |
| Beigene USA, INC. | $20.30 | 2025 | Brukinsa |
| Incyte Corporation | $17.57 | 2023 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $17.00 | 2021 | |
| Amgen INC. | $15.75 | 2023 | Lumakras |
| Adc Therapeutics America, INC. | $13.69 | 2025 | |
| Iovance Biotherapeutics, INC. | $9.37 | 2025 | Amtagvi |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.